- Home
- CANF vs KIRK Comparison
CANF vs KIRK Comparison
Compare CANF & KIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- KIRK
- Stock Information
- Founded
- CANF 1994
- KIRK 1966
- Country
- CANF Israel
- KIRK United States
- Employees
- CANF N/A
- KIRK N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- KIRK Diversified Commercial Services
- Sector
- CANF Health Care
- KIRK Miscellaneous
- Exchange
- CANF Nasdaq
- KIRK Nasdaq
- Market Cap
- CANF 14.8M
- KIRK 17.0M
- IPO Year
- CANF N/A
- KIRK 2002
- Fundamental
- Price
- CANF $1.05
- KIRK $1.18
- Analyst Decision
- CANF Strong Buy
- KIRK Buy
- Analyst Count
- CANF 2
- KIRK 2
- Target Price
- CANF $14.00
- KIRK $4.50
- AVG Volume (30 Days)
- CANF 172.6K
- KIRK 158.7K
- Earning Date
- CANF 05-27-2025
- KIRK 06-05-2025
- Dividend Yield
- CANF N/A
- KIRK N/A
- EPS Growth
- CANF N/A
- KIRK N/A
- EPS
- CANF N/A
- KIRK N/A
- Revenue
- CANF $674,000.00
- KIRK $441,360,000.00
- Revenue This Year
- CANF $461.72
- KIRK $2.76
- Revenue Next Year
- CANF N/A
- KIRK N/A
- P/E Ratio
- CANF N/A
- KIRK N/A
- Revenue Growth
- CANF N/A
- KIRK N/A
- 52 Week Low
- CANF $1.02
- KIRK $1.10
- 52 Week High
- CANF $4.69
- KIRK $2.57
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- KIRK 45.97
- Support Level
- CANF $0.98
- KIRK $1.16
- Resistance Level
- CANF $1.14
- KIRK $1.26
- Average True Range (ATR)
- CANF 0.06
- KIRK 0.09
- MACD
- CANF 0.01
- KIRK -0.00
- Stochastic Oscillator
- CANF 32.59
- KIRK 17.14
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About KIRK Kirkland's Inc. COMMONSTOCK
Kirkland's Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.